Metis Global Partners LLC Has $7.75 Million Stake in Amgen Inc. $AMGN

Metis Global Partners LLC decreased its position in shares of Amgen Inc. (NASDAQ:AMGN) by 8.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 23,673 shares of the medical research company’s stock after selling 2,052 shares during the period. Metis Global Partners LLC’s holdings in Amgen were worth $7,748,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of AMGN. Brighton Jones LLC lifted its position in Amgen by 23.5% during the 4th quarter. Brighton Jones LLC now owns 27,468 shares of the medical research company’s stock worth $7,159,000 after acquiring an additional 5,226 shares during the last quarter. Sivia Capital Partners LLC lifted its position in Amgen by 10.6% during the 2nd quarter. Sivia Capital Partners LLC now owns 1,186 shares of the medical research company’s stock worth $331,000 after acquiring an additional 114 shares during the last quarter. Schnieders Capital Management LLC. lifted its position in Amgen by 29.3% during the 2nd quarter. Schnieders Capital Management LLC. now owns 25,859 shares of the medical research company’s stock worth $7,220,000 after acquiring an additional 5,853 shares during the last quarter. Main Street Financial Solutions LLC lifted its position in Amgen by 11.3% during the 2nd quarter. Main Street Financial Solutions LLC now owns 4,086 shares of the medical research company’s stock worth $1,141,000 after acquiring an additional 416 shares during the last quarter. Finally, Ieq Capital LLC lifted its position in Amgen by 5.1% during the 2nd quarter. Ieq Capital LLC now owns 54,152 shares of the medical research company’s stock worth $15,120,000 after acquiring an additional 2,611 shares during the last quarter. Institutional investors and hedge funds own 76.50% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on AMGN shares. Wall Street Zen lowered shares of Amgen from a “buy” rating to a “hold” rating in a research report on Saturday, June 6th. Piper Sandler cut their target price on shares of Amgen from $432.00 to $427.00 and set an “overweight” rating for the company in a research report on Thursday, May 14th. Jefferies Financial Group began coverage on shares of Amgen in a research report on Tuesday, March 10th. They set a “hold” rating and a $350.00 target price for the company. Leerink Partners reaffirmed a “market perform” rating and set a $355.00 price objective on shares of Amgen in a research report on Thursday, March 5th. Finally, Erste Group Bank reaffirmed a “hold” rating on shares of Amgen in a research report on Tuesday, May 5th. Two research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, fourteen have given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $354.12.

Trending Headlines about Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen’s obesity drug MariTide is drawing attention as a potential growth driver, with analysts noting that its less frequent dosing could help the company compete in the fast-growing GLP-1/obesity market. Article Title
• Positive Sentiment: Amgen’s broader growth pipeline is being viewed as a potential offset to patent-related pressure, with some commentary suggesting 2026 could be a “springboard” year if newer drugs gain traction. Article Title
• Neutral Sentiment: Goldman Sachs trimmed its price target on Amgen but kept a Buy rating, signaling some caution on valuation while still seeing upside potential. Article Title
• Neutral Sentiment: Recent market commentary noted that Amgen has underperformed some peers and posted a bigger drop than the broader market, reflecting short-term profit-taking and weaker relative momentum. Article Title
• Negative Sentiment: Market coverage also flagged that Amgen fell more than the market in the latest session, reinforcing concern that investors may be locking in gains after the stock’s strong multi-year run. Article Title

Insider Activity at Amgen

In other news, SVP Nancy A. Grygiel sold 1,237 shares of the company’s stock in a transaction dated Monday, May 4th. The shares were sold at an average price of $323.73, for a total transaction of $400,454.01. Following the completion of the transaction, the senior vice president owned 7,009 shares of the company’s stock, valued at approximately $2,269,023.57. This represents a 15.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 0.85% of the company’s stock.

Amgen Stock Down 2.0%

Shares of AMGN opened at $337.73 on Thursday. The company has a 50-day simple moving average of $340.89 and a 200-day simple moving average of $345.53. The firm has a market capitalization of $182.28 billion, a P/E ratio of 23.50, a P/E/G ratio of 3.46 and a beta of 0.42. The company has a debt-to-equity ratio of 5.65, a quick ratio of 1.01 and a current ratio of 1.26. Amgen Inc. has a 52 week low of $267.83 and a 52 week high of $391.29.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Thursday, April 30th. The medical research company reported $5.15 EPS for the quarter, beating analysts’ consensus estimates of $4.77 by $0.38. The business had revenue of $8.62 billion during the quarter, compared to analyst estimates of $8.58 billion. Amgen had a net margin of 20.96% and a return on equity of 137.41%. The firm’s revenue for the quarter was up 5.8% on a year-over-year basis. During the same quarter in the prior year, the business earned $4.90 earnings per share. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. On average, equities research analysts expect that Amgen Inc. will post 22.38 earnings per share for the current year.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.